FastWave Medical announced today that it received a fourth utility patent to strengthen the IP foundation of its IVL platform.
Minneapolis-based FastWave develops laser-based intravascular lithotripsy (IVL) technology for treating calcific artery disease. Its platform offers durable and fast energy delivery with enhanced sonic output to navigate complex arterial anatomy through a high-performing catheter.
FastWave’s IVL technology is currently being used in a first-in-human study kicked off earlier this year.
IVL is a fast-growing space, with Johnson & Johnson’s recent $13.3 billion acquisition of Shockwave Medical highlighting that. Learn more about FastWave Medical and IVL at DeviceTalks Boston May 1-2.
The latest patent for FastWave covers the company’s novel next-generation laser-IVL technology.
In a news release, Dr. William Nicholson, a physician advisor for FastWave, said the company’s novel approach “has enormous potential to leapfrog today’s IVL technology with durable, fast, and consistent laser energy.”
Nicholson serves as the director of interventional cardiology at Emory Healthcare. He said the patent also enables FastWave to develop an “ultra-sleek” balloon catheter. This could help overcome the challenges of existing IVL options in reaching and crossing diseased vessels.
“It’s a very exciting time for FastWave and the field of IVL to further enable physicians to optimize procedural outcomes for their patients,” said co-founder and CEO of FastWave Medical, Scott Nelson. “Our growing IP portfolio is a key asset and catalyst to advance IVL technology with novel energy sources and design elements that can expand its use for more patients. I am excited and proud of the FastWave team for their dedication to power innovation that enhances clinical outcomes.”
